title: Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma.
abstract: Twenty-one cases of gastric carcinoma were tested for the presence of Epstein-Barr virus (EBV) genome by polymerase chain reaction (PCR) analysis. EBV genome was detected in 3 (14%) of the 21 cases. In situ hybridization for EBV-encoded small RNA 1 showed that EBV genomes were present in almost all carcinoma cells of the 3 cases. Southern hybridization for terminal repeats of the EBV-DNA revealed that the cases carried an individual monoclonal EBV genome. The analysis demonstrated the presence of linear form of EBV-DNA indicating lytic EBV infection in one of the cases. The expression of EBV genes in the cases was analyzed by reverse transcription-PCR. The mRNA for EBV-determined nuclear antigen (EBNA) initiating from the BamHI-Q promoter was detected, while both BamHI-W and -C promoters were not detected. EBNA2 and latent membrane protein (LMP) 1 mRNAs were not detected in all cases, while LMP2A mRNA was detected in 2 cases. The transcripts of EBV immediate-early genes, BZLF1 and/or BRLF1 were detected in 2 of the cases. The transcripts of late lytic genes (BcLF1 and BLLF1) were detected partly in the 3 cases. Our results indicate that lytic EBV infection occurs in EBV-positive gastric carcinomas.
authors.affiliation: Department of Biosignaling, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Hoshikawa
authors.forename: Yukio
authors.initials: Y
authors.lastname: Satoh
authors.forename: Masanao
authors.initials: M
authors.lastname: Murakami
authors.forename: Michio
authors.initials: M
authors.lastname: Maeta
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kaibara
authors.forename: Hisao
authors.initials: H
authors.lastname: Ito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kurata
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sairenji
mesh_terms: D015139:Blotting, Southern / Q000379:methods; D004279:DNA, Viral / Q000032:analysis; D004268:DNA-Binding Proteins / Q000235:genetics; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000473:pathology / Q000821:virology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000235:genetics; D015870:Gene Expression; D016679:Genome, Viral; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics; D011401:Promoter Regions, Genetic; D012367:RNA, Viral / Q000235:genetics; D013270:Stomach / Q000473:pathology / Q000821:virology; D013274:Stomach Neoplasms / Q000150:complications / Q000473:pathology / Q000821:virology*; D015534:Trans-Activators / Q000235:genetics; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014764:Viral Proteins; D017735:Virus Latency
chemical_list: C068382:BRLF1 protein, Human herpesvirus 4; C063676:BZLF1 protein, Herpesvirus 4, Human; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; C099537:Epstein-Barr virus encoded RNA 1; D017874:Immediate-Early Proteins; D012367:RNA, Viral; D015534:Trans-Activators; D014764:Viral Proteins